Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis. Issue 12 (6th July 2021)

• Record Type: Journal Article
• Authors: Clark, Kristina Elizabeth Neergaard; Campochiaro, Corrado; Csomor, Eszter; Taylor, Adam; Nevin, Katherine; Galwey, Nicholas; Morse, Mary A; Singh, Jennifer; Teo, Yee Voan; Ong, Voon H; Derrett-Smith, Emma; Wisniacki, Nicolas; Flint, Shaun M; Denton, Christopher P
• Is Part Of: Annals of the rheumatic diseases. Volume 80:Issue 12(2021)
• Page Start: 1584
• Page End: 1593
• Publication Date: 2021-07-06
• Subjects: systemic sclerosis -- autoantibodies -- therapeutics; Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2021-220402
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Objectives: Clinical heterogeneity is a cardinal feature of systemic sclerosis (SSc). Hallmark SSc autoantibodies are central to diagnosis and associate with distinct patterns of skin-based and organ-based complications. Understanding molecular differences between patients will benefit clinical practice and research and give insight into pathogenesis of the disease. We aimed to improve understanding of the molecular differences between key diffuse cutaneous SSc subgroups as defined by their SSc-specific autoantibodies Methods: We have used high-dimensional transcriptional and proteomic analysis of blood and the skin in a well-characterised cohort of SSc (n=52) and healthy controls (n=16) to understand the molecular basis of clinical diversity in SSc and explore differences between the hallmark antinuclear autoantibody (ANA) reactivities. Results: Our data define a molecular spectrum of SSc based on skin gene expression and serum protein analysis, reflecting recognised clinical subgroups. Moreover, we show that antitopoisomerase-1 antibodies and anti-RNA polymerase III antibodies specificities associate with remarkably different longitudinal change in serum protein markers of fibrosis and divergent gene expression profiles. Overlapping and distinct disease processes are defined using individual patient pathway analysis. Conclusions: Our findings provide insight into clinical diversity and imply pathogenetic differences between ANA-based subgroups. This supports stratification of SSc cases by ANA antibody subtype in clinical trials and may explain different outcomes across ANA subgroups in trials targeting specific pathogenic mechanisms.